Summary of Prenetics (PRE) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $46.5 million for Q2 2026, up 29% quarter-over-quarter and 3.9x year-over-year.

IM8 Revenue: $45 million, representing a 33% sequential increase with a gross margin of 65%.

Customer Acquisition Cost (CAC): Improved to $239 in July, down 21% from Q2.

Adjusted Free Cash Flow: Positive for the first time in company history as of July.

Net Loss: $9 million for Q2, a 45% improvement from the same period last year ($0.52 per share).

Active Subscribers: 140,000, with 50% having been with the company for over three months.

2Strategic Updates and Business Highlights

Product Launches: Planned launches for IM8 hydration and a premium line of gummies in Q4 2026 and Q1 2027, respectively.

General Catalyst Partnership: Secured $1 billion in funding, which will cover 70% of marketing expenses, allowing for aggressive growth without cash constraints.

Brand Growth: IM8 has achieved significant brand recognition and customer loyalty, with strong word-of-mouth referrals and a growing social media presence.

AI-Native Organization: Operating with a lean team of 70, achieving high revenue per employee and reduced operating costs.

3Forward Guidance and Outlook

Full-Year Revenue Guidance: Raised to $220 million to $230 million, with IM8 contributing $215 million to $222 million.

Q3 Revenue Guidance: Expected between $61.5 million to $62.5 million for IM8.

2027 Revenue Outlook: Projecting over $400 million, with an exit run rate of $300 million by the end of 2026.

Adjusted EBITDA: Expected to improve significantly in the second half of 2026, projecting a loss of $8 million to $12 million.

4Bad News, Challenges, or Points of Concern

Net Loss: Despite improvements, the company still reported a net loss, which could raise concerns among investors.

Competitive Pressures: The supplement market remains competitive, with established brands like Thorne and new entrants posing challenges.

CAC Normalization: While July saw a significant drop in CAC, there is uncertainty about whether this trend will continue into August and beyond.

Dependence on Marketing Spend: The high marketing expenditure (78% of sales) raises questions about long-term sustainability and profitability.

5Notable Q&A Insights

Customer Acquisition Strategy: The company is focusing on direct-to-consumer sales, with 95% of transactions occurring on its website. Retail expansion is not currently planned.

Market Expansion: Currently in 46 countries, with potential future entry into China and India.

Product Development Timeline: New product development typically takes 12 to 18 months, emphasizing a careful and deliberate approach.

Consumer Trends: There is a growing interest in health and wellness across generations, particularly among millennials and Gen Z, which could benefit IM8's product offerings.

Scientific Validation: Ongoing clinical trials are expected to enhance brand credibility and consumer trust, with results anticipated in 2027. Overall, Prenetics is experiencing rapid growth and positive momentum, bolstered by strong financial performance and strategic initiatives, despite facing competitive pressures and ongoing net losses.